NYSE: BMYBristol Myers Squibb Co Stock Forecast, Predictions & Price Target
Analyst price target for BMY
Based on 10 analysts offering 12 month price targets for Bristol Myers Squibb Co.
Min Forecast
$50.00-17.55%
Avg Forecast
$70.40+16.09%
Max Forecast
$80.00+31.93%
Should I buy or sell BMY stock?
Strong Buy
Strong Buy
9 analysts 64.29%
Buy
1 analysts 7.14%
Hold
4 analysts 28.57%
Sell
0 analysts 0.00%
Strong Sell
0 analysts 0.00%
Forecast return on equity
Is BMY forecast to generate an efficient return?
Company
37.01%
Industry
55.96%
Market
-1.56%
BMY's Return on Equity is forecast to be high in 4 years (37.01%); analysts are confident in the firm's ability to efficiently generate return on equity
Forecast
Forecast return on assets
Is BMY forecast to generate an efficient return on assets?
Company
14.19%
Industry
15.11%
Market
11.47%
BMY is forecast to generate lower Return on Assets (14.19%) than the US Drug Manufacturers - General industry average (15.11%)
Forecast
BMY earnings per share forecast
What is BMY's earnings per share in the next 3 years based on estimates from 7 analysts?
Avg 1 year Forecast
$6.25-2,333.68%
Avg 2 year Forecast
$7.28-2,698.46%
Avg 3 year Forecast
$7.70-2,849.11%
BMY revenue forecast
What is BMY's revenue in the next 3 years based on estimates from 4 analysts?
Avg 1 year Forecast
$41.9B+20.32%
Avg 2 year Forecast
$45.3B+29.88%
Avg 3 year Forecast
$47.1B+35.07%
BMY's revenue is forecast to grow at a rate of 10.54% per year, which is not exceptional
Forecast
BMY revenue growth forecast
How is BMY forecast to perform vs Drug Manufacturers - General companies and vs the US market?
Company
10.54%
Industry
6.43%
Market
5.62%
BMY's revenues are forecast to grow faster (10.54% per year) than the US Drug Manufacturers - General industry average (6.43%)
Forecast
BMY's revenues are forecast to grow faster (10.54% per year) than the US market average (5.62%)
Forecast
Bristol Myers Squibb Stock Forecast FAQ
Is Bristol Myers Squibb Stock a good buy in 2020, according to Wall Street analysts?
The consensus among 14 Wall Street analysts covering (NYSE: BMY) stock is to Strong Buy BMY stock.
Out of 14 analysts, 9 (64.29%) are recommending BMY as a Strong Buy, 1 (7.14%) are recommending BMY as a Buy, 4 (28.57%) are recommending BMY as a Hold, 0 (0.00%) are recommending BMY as a Sell, and 0 (0.00%) are recommending BMY as a Strong Sell.
What is BMY's Price Target?
According to 10 Wall Street analysts that have issued a 1 year BMY price target, the average BMY price target is $70.40, with the highest BMY stock price forecast at $80.00 and the lowest BMY stock price forecast at $50.00.
On average, Wall Street analysts predict that Bristol Myers Squibb's share price could reach $70.40 by Oct 19, 2021. The average Bristol Myers Squibb stock price prediction forecasts a potential upside of 16.09% from the current BMY share price of $60.64.
What is BMY's earnings growth forecast for 2020-2022?
(NYSE: BMY) Bristol Myers Squibb's forecast annual earnings growth rate of N/A is not forecast to beat the US Drug Manufacturers - General industry's average forecast earnings growth rate of 20.03%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 14.71%.
Bristol Myers Squibb's earnings in 2020 is -$563,000,000.On average, 7 Wall Street analysts forecast BMY's earnings for 2020 to be $14,151,540,535, with the lowest BMY earnings forecast at $13,983,422,686, and the highest BMY earnings forecast at $14,300,199,252. On average, 7 Wall Street analysts forecast BMY's earnings for 2021 to be $16,462,651,850, with the lowest BMY earnings forecast at $14,956,379,281, and the highest BMY earnings forecast at $16,857,038,675.
In 2022, BMY is forecast to generate $17,417,054,389 in earnings, with the lowest earnings forecast at $16,857,038,675 and the highest earnings forecast at $18,259,906,323.
What is BMY's revenue growth forecast for 2020-2022?
(NYSE: BMY) Bristol Myers Squibb's forecast annual revenue growth rate of 10.54% is forecast to beat the US Drug Manufacturers - General industry's average forecast revenue growth rate of 6.43%, and and it is also forecast to beat the US market's average forecast revenue growth rate of 5.62%.
Bristol Myers Squibb's revenue in 2020 is $34,862,000,000.On average, 4 Wall Street analysts forecast BMY's revenue for 2020 to be $94,912,022,154,526, with the lowest BMY revenue forecast at $94,365,408,351,582, and the highest BMY revenue forecast at $95,439,167,774,818. On average, 4 Wall Street analysts forecast BMY's revenue for 2021 to be $102,449,003,262,705, with the lowest BMY revenue forecast at $101,493,401,498,476, and the highest BMY revenue forecast at $103,538,216,856,967.
In 2022, BMY is forecast to generate $106,549,472,263,614 in revenue, with the lowest revenue forecast at $103,177,589,363,815 and the highest revenue forecast at $109,217,092,977,169.
What is BMY's Earnings Per Share (EPS) forecast for 2020-2022?
(NYSE: BMY) Bristol Myers Squibb's current Earnings Per Share (EPS) is -$0.28. On average, analysts forecast that BMY's EPS will be $6.25 for 2020, with the lowest EPS forecast at $6.18, and the highest EPS forecast at $6.32. On average, analysts forecast that BMY's EPS will be $7.28 for 2021, with the lowest EPS forecast at $6.61, and the highest EPS forecast at $7.45. In 2022, BMY's EPS is forecast to hit $7.70 (min: $7.45, max: $8.07).
What is BMY's forecast return on equity (ROE) for 2020-2023?
(NYSE: BMY) forecast ROE is 37.01%, which is considered strong.
What is BMY's forecast return on assets (ROA) for 2020-2023?
(NYSE: BMY) forecast ROA is 14.19%, which is lower than the forecast US Drug Manufacturers - General industry average of 15.11%.
©2020 WallStreetZen
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
